Bioethics: Life, Death, and the Limits of Medicine

The Birth of Bioethics

Bioethics emerged in the 1960s–70s in response to the rapid development of medical technologies, which raised questions going beyond the boundaries of traditional medical ethics. Organ transplantation, life-support machines, DNA tests, genetic engineering—all this created situations where medicine could do things it previously could not, but it was unclear whether it ought to do them.

The first bioethical scandals set the tone. Tuskegee (1932–1972): four hundred African Americans with syphilis were observed without treatment even after the discovery of penicillin—in order to study the natural course of the disease. This violated the principle of informed consent and respect for patient autonomy. Henrietta Lacks (“HeLa cells”): cancer cells were taken from a patient without her consent, gave rise to an immortal cell line still used today—but the family received neither recognition nor income.

The Four Principles of Bioethics

Tom Beauchamp and James Childress, in "Principles of Biomedical Ethics" (1979, 8 editions), formulated four principles that became the standard:

1. Autonomy—the right of the patient to make decisions about their own treatment based on informed consent. The patient is not an object of treatment but a subject participating in decision-making. This requires: disclosure of information, understanding, voluntariness, capacity.

2. Beneficence—to act in the best interests of the patient. Medicine exists for the benefit of the sick. But who defines "benefit"? The conflict between what the doctor considers beneficial and what the patient wants is the main bioethical collision.

3. Non-maleficence—"first, do no harm." The principle requires avoiding actions whose risks exceed the expected benefits. But medical interventions almost always involve risks—the boundary is blurred.

4. Justice—the fair allocation of medical resources. Who receives a transplant when there are fewer organs than those in need? On what basis—medical necessity? Social value? Lottery?

Difficult Cases

Euthanasia: passive (cessation of treatment) and active (administration of a lethal dose). The Netherlands, Belgium, and Switzerland have legalized one form or another. Arguments for: respect for the autonomy of the suffering patient, prevention of senseless suffering. Arguments against: "slippery slope" (from the severely ill to those "tired of living"), pressure on vulnerable patients, incompatibility with the medical vocation.

Prenatal diagnosis and abortion: the possibility of discovering genetic abnormalities in the fetus before birth raises the question of "designing" children. Eugenic connotations are not a historical curiosity but a real issue.

Organ distribution: transplant waiting lists are an ethically sensitive area. Criteria: medical compatibility, urgency, waiting time, adherence to regimen, social factors? Each criterion carries a value judgment.

Genetic Ethics

CRISPR-Cas9 has opened the possibility of editing the human genome. The case of He Jiankui (2018)—the birth of children with an edited CCR5 gene (HIV resistance) without proper scientific and ethical oversight—provoked a wave of condemnation. Why?

Problems: consent of edited subjects (future children cannot consent); irreversibility of changes; transmission of changes to future generations ("germline"); unequal access to "enhancements"; changing the very concept of human nature.

Here, bioethics intersects with the philosophy of personhood, political theory, and economics. These are not academic questions—they require legislative decisions that will be made in the coming years.